Curaleaf Holdings (CURLF) Operating Expenses (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Operating Expenses of $156.5 million for Q1 2026, up 7.07% year-on-year from $146.2 million in Q1 2025, and up 2.15% on a QoQ basis from $153.2 million in Q4 2025.
Curaleaf Holdings (CURLF) Operating Expenses (2019 - 2026) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Operating Expenses for 8 consecutive years, with $156.5 million the latest figure, recorded in Q1 2026.
- Quarterly Operating Expenses rose 7.07% year-over-year to $156.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $614.8 million (changed 0.12% YoY) and the FY2025 annual result came in at $605.6 million, down 1.7% from the prior year.
- Operating Expenses improved to $156.5 million in Q1 2026 per CURLF's latest filing, from $153.2 million in the prior quarter.
- Over the last five years, Operating Expenses for CURLF reached as high as $142.2 billion in Q4 2023 and fell as low as $134.8 million in Q3 2023.
- A 5-year average of $8.5 billion and a median of $151.3 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses soared 88994.43% — and 2024, when it plunged 99.88%.
- Year by year, Operating Expenses stood at $159.6 million in 2022, then surged by 88994.43% to $142.2 billion in 2023, then tumbled by 99.88% to $163.6 million in 2024, then slipped by 6.34% to $153.2 million in 2025, then rose by 2.15% to $156.5 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $156.5 million, $153.2 million, and $155.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.00 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 788.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 12.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 455.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.24 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 621.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 494.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | 156.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 156.54 Mn |
| Dec 31, 2025 | 153.25 Mn |
| Sep 30, 2025 | 155.71 Mn |
| Jun 30, 2025 | 149.27 Mn |
| Mar 31, 2025 | 146.20 Mn |
| Dec 31, 2024 | 163.63 Mn |
| Sep 30, 2024 | 151.29 Mn |
| Jun 30, 2024 | 152.92 Mn |
| Mar 31, 2024 | 148.20 Mn |
| Dec 31, 2023 | 142.23 Bn |
| Sep 30, 2023 | 134.84 Mn |
| Jun 30, 2023 | 152.04 Mn |
| Mar 31, 2023 | 142.46 Mn |
| Dec 31, 2022 | 159.63 Mn |
| Sep 30, 2022 | 135.18 Mn |
| Jun 30, 2022 | 143.90 Mn |
| Mar 31, 2022 | 135.31 Mn |
| Dec 31, 2021 | 136.24 Mn |
| Sep 30, 2021 | 140.35 Mn |
| Jun 30, 2021 | 130.22 Mn |